Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia

Blood

Volumn 98, Issue 6, 2001, Pages 1708-1713

  Talpaz, Moshe ^a,b   O'Brien, Susan ^a,b   Rose, Esther ^a,b   Gupta, Samir ^a,b   Shan, Jianqin ^a,b   Cortes, Jorge ^a,b   Giles, Francis J ^a,b   Faderl, Stefan ^a,b   Kantarjian, Hagop M ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; SCHERING 54031;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 0035885964     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1708     Document Type: Article

References (42)

1. Kantarjian HM, Deisseroth A, Kurzrock LR, Estrov A, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
2. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069-3081.
3. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;31:207-219.
4. Savage PD, Muss HB. Renal cell cancer. In: De-Vita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia, PA: Lippincott; 1995:373-387.
5. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med. 1993;329:1608-1614.
6. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multi-center randomized trials and summary of other studies. Ann Oncol. 1995;6:467-476.
7. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol. 1996;14:7-17.
8. Talpaz M, Kantarjian H, Kurzrock R, et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114:532-538.
9. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 1995;122:254-261.
10. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
11. Allan NC, Richards SM, Shepherd PCA, et al. UK Medical Research Council randomized, multicenter trial of interferon-α n 1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet. 1995;345:1392-1397.
12. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616-1620.
13. Kantarjian HM, O'Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999;17:284-292.
14. Kantarjian H, Keating M, Estey E, et al. Treatment of advanced Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J Clin Oncol. 1992;10:772-778.
15. Arthur CK, Ma DFF. Combined interferon apha-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol. 1993;89(suppl 1):15-21.
16. Thaler J, Hilbe W, Apfelbeck U, et al. Interferon-alpha-2c and low-dose ara-C for the treatment of patients with CML: results of the Austrian multicenter phase study. Leuk Res. 1997;21:75-80.
17. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl M Med. 1997;337:223-229.
18. Rosti G, Bonifazi F, De Vivo A, et al. Cytarabine increases karyotypic response and survival in αIFN treated chronic myelogenous leukemia patients: results of a national prospective randomized trial of the Italian Cooperative Study Group on CML [abstract]. Blood. 1999;94:600a.
19. Ansari H, Hasford J, Hehlmann R. Fallacies of the intention-to-treat analysis. The German CML Study Group [abstract]. J Mol Med. 1997;75:8243.
20. Talpaz M, Kantarjian H. Low-dose interferon-a in chronic myelogenous leukemia. Ann Intern Med. 1995;122:728-729.
21. 1-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood. 1988;72:642-647.
22. Francis GE, Fisher D, Delgado C, Malik F, Gardiner A, Neale D. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol. 1998;68:1-18.
23. Francis GE, Delgado C, Fisher D, Malik F, Agrawal AK. Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J Drug Target. 1996;3:321-340.
24. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 2000;39:10634-10640.
25. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780-1786.
26. Ettinger LJ, Asselin B, Poplack DG, Kurtzberg J. Toxicity profile of PEG-L-asparaginase in native-L-asparaginase hypersensitive and non-hyper-sensitive patients with acute lymphoblastic leukemia (ALL). Med Pediatr Oncol. 1993;21:556-560.
27. Kotasek D, The ARANESP 980291 Study Group, Berg R, Poulsen E, Colowick A. Randomized, double-blind, placebo controlled, phase I/II dose finding study of ARANESP administered once every three weeks in solid tumor patients [abstract]. Blood. 2000;96:294a.
28. Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor increased platelet counts in patients with aplastic anemia and myelodysplastic syndrome [abstract]. Blood. 2000;96:296a.
29. Bolwell B, Vredenburg J, Overmoyer B, et al. Phase I study of pegylated recombinant human megakaryocyte growth and development factor in breast cancer patients after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 2000;26:141-145.
30. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci U S A. 2000;97:8548-8553.
31. Safra T, Groshen S, Jeffers S, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Cancer. 2001;91:90-100.
32. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest. 1992;89:1643-1651.
33. Kitamura K, Takahashi T, Takashina K, et al. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun. 1990;171:1387- 1394.
34. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alpha-2 in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
35. Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680.
36. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: an analysis of 242 patients. Am J Med. 1987;83:445-454.
37. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
38. 195-010 Study Report Data on file, Schering-Plough Research Institute; Kenilworth, NJ.
39. 195-060. Data on file, Schering-Plough Research Institute; Kenilworth, NJ.
40. Obenauer-Kutner LJ, Jacobs SJ, Kolz K, Tobias LM, Bordens RW. A highly sensitive electrochemiluminescence immunoassay for interferon alfa-2b in human serum. J Immunol Methods. 1997;206:25-33.
41. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, 1982;409-417.
42. National Cancer Institute Common Toxicity Criteria, version 2.0 (1.30.1998). http://ctep.info.nih. gov. Accessed January 2001.